Abstract
Immune checkpoint inhibitors (ICIs) have had a significant impact on the prognosis of people with a wide range of tumours. Melanoma in particular is one of the malignancies for which immunotherapy can achieve excellent outcomes in the adjuvant and advanced settings. Here the authors discuss the use of ICIs and the benefits they can offer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
